The KEYNOTE‐024 study showed that in metastatic NSCLC patients with at least 50% PD‐L1‐positive tumour cells, compared with platinum‐based chemotherapy, pembrolizumab prolonged PFS by 4.3 months and increased the 6‐month overall survival (OS) rate from 72.4% to 80.2% [2]. Here, CD274 is linked to non-small cell lung carcinoma.